Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
23 Maggio 2024 - 10:05PM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders
that it will hold its 2024 Annual Meeting of Stockholders on
Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will
be held in virtual format only via live audio webcast.
Vir Biotechnology’s stockholders of record at the close of
business on April 1, 2024, the record date for the Annual Meeting,
can attend and vote at the Annual Meeting by accessing the meeting
center at www.virtualshareholdermeeting.com/VIR2024 and entering
the control number on the proxy card or Notice of Internet
Availability of Proxy Materials previously received. Instructions
on how to connect to the Annual Meeting and participate via the
Internet are also posted at
www.virtualshareholdermeeting.com/VIR2024. Online access to the
Annual Meeting will begin at 8:45 a.m. PT on May 29, 2024.
Stockholders should allow ample time for the check-in
procedures.
Whether or not stockholders plan to virtually attend the Annual
Meeting, Vir Biotechnology urges them to vote and submit their
proxy in advance of the Annual Meeting by one of the methods
described in the proxy materials for the Annual Meeting.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on
powering the immune system to transform lives by treating and
preventing infectious diseases and other serious conditions,
including viral-associated diseases. Vir has assembled two
technology platforms that are designed to modulate the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523355863/en/
Media Carly Scaduto Senior Director, External
Communications cscaduto@vir.bio +1 314-368-5189
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio +1 978-973-9986
Grafico Azioni Vir Biotechnology (NASDAQ:VIR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Vir Biotechnology (NASDAQ:VIR)
Storico
Da Gen 2024 a Gen 2025
